Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 3-(benzoyl phenyl) propionic acid derivative in treatment of connexin CX31 mediated skin diseases

A cyclopentyloxybenzoyl, skin disease technology, applied in the field of pharmacy, can solve problems such as poor curative effect

Inactive Publication Date: 2015-04-29
TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE +1
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Therefore, aiming at the problem of poor curative effect of drugs used to treat connexin CX31-mediated skin diseases in the prior art, the present invention provides 3-{[2-[3-oxo-(1,2-benzoisoxan Azol-6-yl)methoxy]-5-[(2-hydroxy-4-cyclopentyloxybenzoyl)]phenyl}propionic acid (I) was used in the preparation of connexin CX31-mediated skin application in medicines for diseases, especially in the preparation of medicines for the treatment of variable erythematous keratoderma or psoriasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 3-(benzoyl phenyl) propionic acid derivative in treatment of connexin CX31 mediated skin diseases
  • Application of 3-(benzoyl phenyl) propionic acid derivative in treatment of connexin CX31 mediated skin diseases
  • Application of 3-(benzoyl phenyl) propionic acid derivative in treatment of connexin CX31 mediated skin diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only some, not all, embodiments of the present invention. All other embodiments obtained by persons of ordinary skill in the art based on the embodiments of the present invention belong to the protection scope of the present invention.

[0022] 1. Chemical synthesis part

[0023] 1.1 Synthesis of 6-[(2,4-methoxyphenyl)carbonyl]-coumarin

[0024] Add 25g of 6-methylcoumarin and chlorobenzene (25mL) into 62.5% sulfuric acid (150mL), stir and heat up. At 70-90°C, add 30g of active manganese dioxide in 8 times, and add 62.5% sulfuric acid (19mL) dropwise at 70-90°C. Control the temperature at 80-90°C and stir for 1h. Cool to room temperature. Add about 150mL of water, dropwise add 43mL of 20% ammonia water, 100mL of ethyl a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a 3-[[2-[3-oxo-(1, 2-benzisoxazole-6-yl) methoxyl]-5-[(2-hydroxyl-4-cyclopentoxyl benzoyl)] phenyl] propionic acid (compound I) in preparation for treatment of connexin CX31 mediated skin disease. The connexin CX31 mediated skin disease comprises erythrokeratodermia variabilis or psoriasis. The pharmacological experiment proves that a low-dose group and a high-dose group of the compound I can remarkably reduce skin damage degree of a psoriasis animal sample; the content of TNF-alpha in murine serum can be restrained by the low-dose group of the compound I, then inflammatory cell infiltration is restrained, the inflammatory response is relieved, and the compound I has good psoriasis treatment effect and can be used for treating the connexin CX31 mediated skin disease.

Description

technical field [0001] The present invention relates to the field of pharmacy, in particular to 3-{[2-[3-oxo-(1,2-benzisoxazol-6-yl)methoxy]-5-[(2-hydroxyl- Application of 4-cyclopentyloxybenzoyl)]phenyl}propionic acid compound in the preparation and treatment of skin diseases mediated by connexin CX31. Background technique [0002] Psoriasis, commonly known as "psoriasis", is a common chronic inflammatory skin disease characterized by scaly erythema. The age of onset is mostly young adults, and men are slightly more than women. It has characteristic red papules, plaques, and silvery white scales, which tend to occur on the scalp and extremities. The onset has obvious seasonality, and it is easy to recur or aggravate in spring and winter, and it is usually relieved in summer and autumn. Clinically divided into two types of psoriasis vulgaris and unusual psoriasis. Unusual psoriasis includes pustular, articular, and erythrodermic types, which are relatively rare, accounting...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/423A61P17/00A61P17/06
Inventor 饶子和张灼华杨诚陈卫强王丹玲张炜程夏昆付文华赵佩佩
Owner TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com